Blueprint
Exhibit 99.1
GT BIOPHARMA ANNOUNCES DR. RAYMOND W URBANSKI ELEVATED TO PRESIDENT
AND CHIEF MEDICAL OFFICER OF THE COMPANY
LOS
ANGELES, CA, May 14, 2018 - GT Biopharma Inc. (OTCQB: GTBP and
Euronext Paris "GTBP.PA") today announced the promotion of Dr.
Raymond W Urbanski MD, PhD to the position of President and Chief
Medical Officer effective immediately. Dr. Urbanski will report to
Shawn Cross, the Company’s Chief Executive
Officer.
“I
am pleased to announce the promotion of Dr. Urbanski to President
and Chief Medical Officer. The combination of Ray’s
experience as a practicing physician and subsequently experience in
industry, where he has served in key leadership positions including
serving as the Chief Medical Officer of one of Pfizer’s
business units and as the Chief Medical Officer of Mylan. His
training, depth of knowledge and experience as well as his
organizational acumen has been invaluable as we prepare GT
Biopharma for our next stage of growth,” said Shawn M. Cross,
Chairman and Chief Executive Officer of GT Biopharma. “In
addition to pushing forward our pre-clinical and clinical product
candidates, Ray has played a critical role in advancing other
company initiatives including recruiting experienced members to our
scientific advisory board and board of directors, implementing
internal processes and procedures, which are less visible but very
important, as progress towards certain goals including a NASDAQ
up-listing, among others. In short, I am delighted to have Ray as a
senior member of our leadership team.”
Since
joining the company in October 2017 Dr. Urbanski has been
instrumental in driving key milestones and initiatives including
the transitioning the first TriKE IND from the University of
Minnesota to GT Biopharma while engaging the FDA in preparation for
human clinical testing to begin in 2H 2018; implementing processes
to expedite the identification and development of future tumor
antigen targets; driving forward our Bi-specific Antibody Drug
Conjugate platform which included the formation of our
Antibody-Drug Conjugate Clinical Advisory Board. Dr. Urbanski has
also been a major factor in developing a strong working
relationship with the University of Minnesota, Masonic Cancer
Center, the epicenter of innovation for the TriKE and TetraKE
platforms.
Dr.
Urbanski also represents the company at key international meetings
such as ASH and the upcoming ASCO conferences, attending investor
conferences and recruiting top tier Scientific Advisory Board
members and consultants.
About GT Biopharma, Inc.
GT
Biopharma, Inc. is an immuno-oncology biotechnology company focused
on innovative treatments based on the company’s proprietary
Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™
and TetraKEs) and bispecific antibody-drug conjugate (ADC)
platforms. GT's lead oncology drug candidate, OXS-1550 (DT2219) is
a novel bispecific scFv recombinant fusion protein-drug conjugate
composed of the variable regions of the heavy and light chains of
anti-CD19 and anti-CD22 antibodies and a modified form of
diphtheria toxin as its cytotoxic drug payload. OXS-1550 has
demonstrated success in early human clinical trials in patients
with relapsed/refractory B-cell lymphoma or leukemia. In addition,
GT's TriKE platform will address a number of cancer types. GT's
nervous system platform is focused on acquiring or discovering and
patenting late-stage, de-risked, and close-to-market improved
treatments for nervous system diseases (Neurology and Pain) and
shepherding them through the approval process to the NDA. GT
Biopharma's neurology products currently include PainBrake, as well
as treatments for the symptoms of myasthenia gravis, and motion
sickness.
Except
for historical information contained herein, the statements in this
release are forward-looking and made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are inherently unreliable and actual
results may differ materially. Examples of forward-looking
statements in this news release include statements regarding the
effectiveness of the Company's products, the potential outcome of
clinical studies, the future success of development activities, the
future growth and operating and financial performance of the
Company and the possibility of the Company uplisting to NASDAQ.
Factors which could cause actual results to differ materially from
these forward-looking statements include such factors as the
Company's ability to accomplish its business initiatives, obtain
regulatory approval and protect its intellectual property;
significant fluctuations in marketing expenses and ability to
achieve or grow revenue, or recognize net income, from the sale of
its products and services, as well as the introduction of competing
products, or management's ability to attract and maintain qualified
personnel necessary for the development and commercialization of
its planned products; the Company's ability to meet the applicable
NASDAQ uplisting requirements, and other information that may be
detailed from time to time in the Company's filings with the United
States Securities and Exchange Commission. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact:
Westwicke
Partners
John
Woolford
(443)
213-0506
john.woolford@westwicke.com